PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Positive EBIT growth while RVPH is negative. John Neff might see a substantial edge in operational management.
-121.69%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-139.60%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-131.82%
Negative EPS growth while RVPH is at 11.32%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-131.82%
Negative diluted EPS growth while RVPH is at 11.32%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while RVPH is at 9.96%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.70%
Negative FCF growth while RVPH is at 9.96%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while RVPH stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
Positive long-term OCF/share growth while RVPH is negative. John Neff would see a structural advantage in sustained cash generation.
75.95%
5Y OCF/share CAGR above 1.5x RVPH's 50.10%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
7.00%
3Y OCF/share CAGR under 50% of RVPH's 50.36%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
81.58%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
47.75%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
-122.09%
Negative 3Y CAGR while RVPH is 66.84%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.45%
Negative equity/share CAGR over 10 years while RVPH stands at 87.30%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
58.16%
Positive 5Y equity/share CAGR while RVPH is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.90%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
60.05%
We increase R&D while RVPH cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
SG&A growth well above RVPH's 51.19%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.